Patent: RE39548
✉ Email this page to a colleague
Summary for Patent: RE39548
Title: | Interleukin-5 specific recombinant antibodies |
Abstract: | An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody. |
Inventor(s): | Bodmer; Mark William (Cambridge, GB), Athwal; Diljeet Singh (London, GB), Emtage; John Spencer (Del Mar, CA) |
Assignee: | Celltech R&D Limited (Slough, Berkshire, GB) |
Application Number: | 10/012,579 |
Patent Claims: | see list of patent claims |
Details for Patent RE39548
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Teva Respiratory, Llc | CINQAIR | reslizumab | Injection | 761033 | March 23, 2016 | ⤷ Sign Up | 2014-06-17 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent RE39548
Country | Patent Number | Estimated Expiration |
---|---|---|
Austria | E264389 | ⤷ Sign Up |
Australia | 2680395 | ⤷ Sign Up |
Australia | 694783 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |